Globus Medical (GMED) Reports In-Line Q2 EPS

Go back to Globus Medical (GMED) Reports In-Line Q2 EPS

Leerink Partners Raises Price Target on Globus Medical (GMED) Following 2Q Results

July 31, 2015 9:46 AM EDT

Leerink Partners reiterated an Outperform rating on Globus Medical (NYSE: GMED), and raised the price target to $32.00 (from $30.00), following 2Q results. 2Q sales of $134MM beat consensus by $7M. EPS was reported in line with consensus estimates of $0.25. GMED raised 2015 revenue... More